Published in Drug Week, July 2nd, 2004
Moreover, patients in the 3-week study receiving Risperdal achieved significantly higher rates of remission as defined by a well-validated scale measuring manic symptoms. The findings appear in the June issue of The American Journal of Psychiatry.
"Bipolar disorder can be devastating. Manic behavior can cause huge problems for the patient and his or her family. The ability to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.